SRTA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
SRTA is not a good buy right now for an impatient investor. Price is breaking below near-term support (~4.96) with bearish momentum (MACD histogram negative and expanding), and pattern-based odds also skew negative over the next day/week. With no Intellectia buy signals today and profitability metrics collapsing YoY in the latest quarter, the risk/reward is unfavorable at the current ~$4.88–$4.90 area.
Trend/Momentum: Bearish. MACD histogram is -0.117 and negatively expanding, suggesting downside momentum is strengthening. RSI(6) at 28.3 is effectively oversold, which can allow for short bounces, but oversold alone is not a buy signal when MACD is still deteriorating.
Levels: Current price (4.9) is below S1 (4.957) and above S2 (4.685). This puts SRTA in a weak zone where failed reclaim of ~4.96 increases the chance of testing ~4.69. The pivot (5.396) is the key upside reclaim level; SRTA would need to get back above it to shift the near-term structure bullish.
Moving averages: Converging MAs indicate compression/indecision, but current momentum signals still point down.
Stat/pattern read: Similar candlestick-pattern analysis implies a 70% probability of further declines (next day -1.65%, next week -2.65%, next month -1.49%).
Intellectia Proprietary Trading Signals
near oversold can trigger short rebounds if price reclaims ~4.96 quickly.
Momentum deterioration: MACD histogram negative and expanding points to ongoing selling pressure.
Latest quarter (2025/Q3): Revenue increased to 49.30M (+36.70% YoY) and gross margin improved to 23.56 (+13.16% YoY), showing top-line growth and some operational improvement. However, profitability deteriorated sharply: net income fell to 57.42M (-3038.38% YoY) and EPS dropped to 0.7 (-2433.33% YoY). The combination (strong revenue, collapsing earnings) suggests either heavy one-time charges, non-operating impacts, or cost/structure issues—without clarifying details, the market typically treats this as high risk.
No analyst rating/price-target change data was provided, so there is no observable recent trend in Wall Street upgrades/downgrades or target revisions. Net takeaway: without external analyst support signals, the decision leans more heavily on the currently bearish technicals and the mixed (top-line strong, bottom-line weak) latest-quarter fundamentals.
